Trimel Pharmaceuticals Corporation
| Change | 0.00 | 0.00% |
| Volume | 0 | |
| 52 week | Low | Hi |
| $0.76 | $3.57 | |
| Financial Information | |
| Shares Outstanding: | 148,296,762 |
| (As per management) | |
| Fully Diluted Shares: | 166,000,000 |
| (As per management) | |
| Est. Market Float: | - |
| Market Cap.: | $118,637,410 |
| Last Declared Dividend: | - |
| EPS last 3 months : | $(0.09) |
| EPS Trailing 12 months: | $(0.20) |
| Long-Term Debt: | $6,582,041 |
| Financial Year-End: | Dec 31 |
15-20 minutes delay
Renmark Financial Disclaimer
This document is published for general information only and it should not be interpreted as an investment recommendation nor an offer or a solicitation to buy or sell securities issued by the said company. Renmark does not and will not accept any responsibility or liability for investment decisions made on the basis of the information herein contained.
Trimel Pharmaceuticals Corporation (TSX:TRL) - Developing medications for Men’s Health, Female Sexual Dysfunction and Respiratory Therapy. Trimel is developing multiple product opportunities, including CompleoTRT™, a bioadhesive intranasal testosterone gel that has successfully completed Phase III clinical efficacy testing in the United States. CompleoTRT™ is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com.
Tom Rossi – President & Chief Executive Officer
Kenneth Howling – Chief Financial Officer
Rolf K. Reininghaus – Executive Director
Matthew Hawkins – Vice President, Legal Affairs & Corporate Secretary
Wayne Kreppner – Vice President, Product Development
Bruce D. Brydon - Chairman
John Friedrichsen - Director
Stephen Gregory - Director
Rolf K. Reininghaus - Director
Jeffrey Sherman - Director
Dr. D. Lorne Tyrrell - Director
- Interview request
- Media Information
- Company Factsheet
- SEDAR filings
Headquarters:
2488 Dunwin DriveMississauga, Ontario
L5L 1J9 Canada